Literature DB >> 12662376

Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.

Hans-Joachim Ulmer1, Andree Beckerling, Gudrun Gatz.   

Abstract

INTRODUCTION: For the eradication of Helicobacter pylori a 1-week triple therapy combining proton pump inhibitors with two antibiotics has been recommended as a gold standard therapy. However, a recent broad data review on the efficacy of the different regimens is missing. Therefore, the aim of this study was to systematically review the recent literature.
METHODS: We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics. Relevant original papers on H. pylori eradication in adults, published in English or German between 1995 and 2000, were identified from MEDLINE searches. Studies were reviewed and selected according to predefined criteria.
RESULTS: Our predefined criteria were fulfilled by 79 full paper articles including 112 study arms with 8383 patients on intention-to-treat, or 6787 patients on per-protocol basis, respectively. The mean eradication rates unweighted or weighted by the number of patients in the study arm vary from 71.9% to 83.8% for intention-to-treat analysis and from 78.5% to 91.2% for per-protocol analysis.
CONCLUSIONS: All nine PPI based triple therapy regimens are very effective in H. pylori eradication. The current literature review underlines that the use of either lansoprazole, omeprazole, or pantoprazole combined with two antibiotics yield similar high eradication rates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662376     DOI: 10.1046/j.1523-5378.2003.00129.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  10 in total

1.  Laparoscopic treatment of gastroduodenal perforations: comparison with conventional surgery.

Authors:  B Kirshtein; M Bayme; T Mayer; L Lantsberg; E Avinoach; S Mizrahi
Journal:  Surg Endosc       Date:  2005-09-27       Impact factor: 4.584

2.  Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation.

Authors:  Jianhua Cai; Cong Han; Tiancen Hu; Jian Zhang; Dalei Wu; Fangdao Wang; Yunqing Liu; Jianping Ding; Kaixian Chen; Jianmin Yue; Xu Shen; Hualiang Jiang
Journal:  Protein Sci       Date:  2006-08-01       Impact factor: 6.725

3.  Effect of high-dose aspirin on Helicobacter pylori eradication.

Authors:  Seung Ha Park; Dong Il Park; Sang Hoon Kim; Hong Joo Kim; Yong Kyun Cho; In Kyung Sung; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Keuk Keum
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

4.  Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.

Authors:  Orhan Sezgin; Mehmet Kasım Aydın; Asena Ayça Özdemir; Arzu Emine Kanık
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

5.  Development of Genetically Encoded Biosensors for Reporting the Methyltransferase-Dependent Biosynthesis of Semisynthetic Macrolide Antibiotics.

Authors:  Yiwei Li; Megan Reed; H Tonie Wright; T Ashton Cropp; Gavin J Williams
Journal:  ACS Synth Biol       Date:  2021-09-21       Impact factor: 5.249

6.  Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.

Authors:  Full-Young Chang; Chih-Yen Chen; Ching-Liang Lu; Jiing-Chyuan Luo; Rei-Hwa Lu; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

7.  Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia.

Authors:  Eyad M Salem; Talay Yar; Abdullah O Bamosa; Abdulaziz Al-Quorain; Mohamed I Yasawy; Raed M Alsulaiman; Muhammad A Randhawa
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

8.  The inhibitory effect of flavonoids on interleukin-8 release by human gastric adenocarcinoma (AGS) cells infected with cag PAI (+) Helicobacter pylori.

Authors:  Mariusz A Skiba; Kornelia Szendzielorz; Bogdan Mazur; Wojciech Król
Journal:  Cent Eur J Immunol       Date:  2016-10-25       Impact factor: 2.085

9.  Helicobacter pylori and Gastroesophageal Reflux Disease.

Authors:  Richard M. Peek
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

10.  Emodin targets the beta-hydroxyacyl-acyl carrier protein dehydratase from Helicobacter pylori: enzymatic inhibition assay with crystal structural and thermodynamic characterization.

Authors:  Jing Chen; Liang Zhang; Yu Zhang; Haitao Zhang; Jiamu Du; Jianping Ding; Yuewei Guo; Hualiang Jiang; Xu Shen
Journal:  BMC Microbiol       Date:  2009-05-12       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.